Last reviewed · How we verify
InfanrixTM penta
Infanrix penta is a pentavalent vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
Infanrix penta is a pentavalent vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | InfanrixTM penta |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pentavalent inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, inactivated poliovirus, and Haemophilus influenzae type b conjugate antigen. These components trigger adaptive immune responses, generating humoral and cellular immunity to protect against these five infectious diseases. The acellular pertussis component reduces reactogenicity compared to whole-cell vaccines.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
- Vomiting
Key clinical trials
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- InfanrixTM penta CI brief — competitive landscape report
- InfanrixTM penta updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI